Subtype‐specific peripheral blood gene expression profiles in recent‐onset juvenile idiopathic arthritis

MG Barnes, AA Grom, SD Thompson… - … : Official Journal of …, 2009 - Wiley Online Library
MG Barnes, AA Grom, SD Thompson, TA Griffin, P Pavlidis, L Itert, N Fall, DP Sowders…
Arthritis & Rheumatism: Official Journal of the American College …, 2009Wiley Online Library
Objective To identify differences in peripheral blood gene expression between patients with
different subclasses of juvenile idiopathic arthritis (JIA) and healthy controls in a multicenter
study of patients with recent‐onset JIA prior to treatment with disease‐modifying
antirheumatic drugs (DMARDs) or biologic agents. Methods Peripheral blood mononuclear
cells (PBMCs) from 59 healthy children and 136 patients with JIA (28 with enthesitis‐related
arthritis [ERA], 42 with persistent oligoarthritis, 45 with rheumatoid factor [RF]–negative …
Objective
To identify differences in peripheral blood gene expression between patients with different subclasses of juvenile idiopathic arthritis (JIA) and healthy controls in a multicenter study of patients with recent‐onset JIA prior to treatment with disease‐modifying antirheumatic drugs (DMARDs) or biologic agents.
Methods
Peripheral blood mononuclear cells (PBMCs) from 59 healthy children and 136 patients with JIA (28 with enthesitis‐related arthritis [ERA], 42 with persistent oligoarthritis, 45 with rheumatoid factor [RF]–negative polyarthritis, and 21 with systemic disease) were isolated from whole blood. Poly(A) RNA was labeled using a commercial RNA amplification and labeling system (NuGEN Ovation), and gene expression profiles were obtained using commercial expression microarrays (Affymetrix HG‐U133 Plus 2.0).
Results
A total of 9,501 differentially expressed probe sets were identified among the JIA subtypes and controls (by analysis of variance; false discovery rate 5%). Specifically, 193, 1,036, 873, and 7,595 probe sets were different in PBMCs from the controls compared with those from the ERA, persistent oligoarthritis, RF‐negative polyarthritis, and systemic JIA patients, respectively. In patients with persistent oligoarthritis, RF‐negative polyarthritis, and systemic JIA subtypes, up‐regulation of genes associated with interleukin‐10 (IL‐10) signaling was prominent. A hemoglobin cluster was identified that was underexpressed in ERA patients but overexpressed in systemic JIA patients. The influence of JAK/STAT, ERK/MAPK, IL‐2, and B cell receptor signaling pathways was evident in patients with persistent oligoarthritis. In systemic JIA, up‐regulation of innate immune pathways, including IL‐6, Toll‐like receptor/IL‐1 receptor, and peroxisome proliferator–activated receptor signaling, were noted, along with down‐regulation of gene networks related to natural killer cells and T cells. Complement and coagulation pathways were up‐regulated in systemic JIA, with a subset of these genes being differentially expressed in other subtypes as well.
Conclusion
Expression analysis identified differentially expressed genes in PBMCs obtained early in the disease from patients with different subtypes of JIA and in healthy controls, providing evidence of immunobiologic differences between these forms of childhood arthritis.
Wiley Online Library